Extracellular ATP hydrolysis in Caco-2 human intestinal cell line

Extracellular nucleotides and nucleosides activate signaling pathways that play major roles in the physiology and pathophysiology of the gastrointestinal tract. Ectonucleotidases hydrolyze extracellular nucleotides and thus regulate ligand exposure to purinergic receptors. In this study, we investigated the expression, localization and activities of ectonucleotidases using Caco-2 cells, a model of human intestinal epithelial cells. In addition, by studying ATP release and the rates of extracellular ATP (eATP) hydrolysis, we analyzed the contribution of these processes to the regulation of eATP in these cells. Results show that Caco-2 cells regulate the metabolism of eATP and by-products by ecto-nucleoside triphosphate diphosphohydrolase-1 and -2, a neutral ecto-phosphatase and ecto-5′-nucleotidase. All these ectoenzymes were kinetically characterized using intact cells, and their presence confirmed by denatured and native gels, western blot and cytoimmunofluorescence techniques. In addition, regulation of eATP was studied by monitoring the dynamic balance between intracellular ATP release and ectoATPase activity. Following mechanical and hypotonic stimuli, Caco-2 cells triggered a strong but transient release of intracellular ATP, with almost no energy cost, leading to a steep increase of eATP concentration, which was later reduced by ectoATPase activity. A data-driven algorithm allowed quantifying and predicting the rates of ATP release and ATP consumption contributing to the dynamic accumulation of ATP at the cell surface.Fil: Schachter, Julieta. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Química y Físico-Química Biológicas "Prof. Alejandro C. Paladini". Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Instituto de Química y Físico-Química Biológicas; ArgentinaFil: Alvarez, Cora Lilia. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Química y Físico-Química Biológicas "Prof. Alejandro C. Paladini". Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Instituto de Química y Físico-Química Biológicas; ArgentinaFil: Bazzi, Zaher. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Química y Físico-Química Biológicas "Prof. Alejandro C. Paladini". Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Instituto de Química y Físico-Química Biológicas; ArgentinaFil: Faillace, Maria Paula. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Fisiología y Biofísica Bernardo Houssay. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Fisiología y Biofísica Bernardo Houssay; ArgentinaFil: Corradi, Gerardo Raul. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Química y Físico-Química Biológicas "Prof. Alejandro C. Paladini". Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Instituto de Química y Físico-Química Biológicas; ArgentinaFil: Hattab, C.. Universite de Paris. Institut National de la Transfusion Sanguine.; FranciaFil: Rinaldi, Debora Eugenia. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Química y Físico-Química Biológicas "Prof. Alejandro C. Paladini". Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Instituto de Química y Físico-Química Biológicas; ArgentinaFil: Gonzalez-Lebrero, Rodolfo Martin. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Química y Físico-Química Biológicas "Prof. Alejandro C. Paladini". Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Instituto de Química y Físico-Química Biológicas; ArgentinaFil: Pucci Molineris, Melisa Eliana. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - La Plata. Instituto de Investigaciones Bioquímicas de La Plata "Prof. Dr. Rodolfo R. Brenner". Universidad Nacional de la Plata. Facultad de Ciencias Médicas. Instituto de Investigaciones Bioquímicas de La Plata "Prof. Dr. Rodolfo R. Brenner"; ArgentinaFil: Sévigny, J.. Laval University; CanadáFil: Ostuni, M. A.. Universite de Paris; Francia. Universite Paris D. Diderot - Paris 7. French National Institute Of Blood Transfusion.; FranciaFil: Schwarzbaum, Pablo Julio. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Química y Físico-Química Biológicas "Prof. Alejandro C. Paladini". Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Instituto de Química y Físico-Química Biológicas; Argentin

Determinação da dose de controle de Urochloa decumbens pela aplicação de glyphosate

The species Urochloa decumbens is an important weed of agricultural crops due to the high adaptive capacity and difficulty of management. The presence of these plants into agricultural production areas can cause serious problems when it competes for water, light and nutrients, besides acting as host of pests and common pathogens to the crop and interfering in harvesting. The study aimed to evaluate doses of control of U. decumbens plants by glyphosate application. Three experiments were conducted, in greenhouse in completely randomized design with six replications, containing between 50 and 80 plants per replication, and eight doses of glyphosate (0, 22.5, 45, 90, 180, 360, 720 and 1440 g ha-1 a.e.). Visual evaluations of injury were performed at 0, 7, 14 and 21 days after application, and collecting eight plants per pot and per treatment to determine dry mass in each evaluated time. For the response curves, the total dry mass was considered, adding all the collected times and the remaining plants from the pots at the end of the experiments. U. decumbens plants treated with 180 g ha-1 a.e. of glyphosate reduced the dry mass in relation to the control, demonstrating greater sensitivity in the application of doses below those recommended and used in the field. In conclusion, the dose 80 g ha-1 a.e. of glyphosate controlled U. decumbens plants causing injury close to 100% and the estimated doses between 30 and 62 g ha-1 a.e. of glyphosate were able to reduce 50 % of plant growthA espécie Urochloa decumbens é uma importante planta daninha de culturas agrícolas devido à alta capacidade adaptativa e dificuldade de manejo. A presença dessas plantas em áreas de produção agrícola pode gerar problemas quando compete por água, luz e nutrientes, além de atuar como hospedeira de pragas e patógenos comuns à cultura e interferir na colheita. O trabalho objetivou avaliar doses de controle de plantas de U. decumbens pela aplicação de glyphosate. Foram realizados três experimentos, em casa de vegetação, em delineamento inteiramente casualizado com seis repetições, contendo entre 50 e 80 plantas por repetição, e oito doses de glyphosate (0; 22,5; 45; 90; 180; 360; 720 e 1440 g ha-1 e.a.). Foram realizadas avaliações visuais de fitotoxicidade aos 0, 7, 14 e 21 dias após a aplicação, e coleta de oito plantas por vaso e por tratamento para determinação de massa seca em cada período avaliado. Para as curvas de resposta, considerou-se a massa seca total, somando todos os períodos coletados, além das plantas remanescentes nos vasos ao término dos experimentos. Plantas de U. decumbens tratadas com 180 g ha-1 e.a. de glyphosate reduziram a massa seca em relação à testemunha, demonstrando maior sensibilidade na aplicação de doses abaixo das recomendadas e utilizadas em campo. Pode-se concluir que a dose 80 g ha-1 e.a. de glyphosate controlou as plantas de U. decumbens, causando fitotoxicidade próxima a 100%, e as doses estimadas entre 30 e 62 g ha-1 e.a. de glyphosate foram capazes de reduzir 50% o crescimento das planta

Minimal intervention in dentistry : which is the best approach for silorane composite restoration repairs?

This study aimed to evaluate surface treatments, adhesives and composites for repairing silorane based restorations. One hundred and twenty truncated cones (2 mm smaller diameter and 4 mm larger diameter) made of silorane composite were divided in 12 g

Evaluation of acute oral toxicity and diuretic activity of Rudgea viburnoides (Cham.) Benth. (congonha-de-bugre)

Rudgea viburnoides é utilizada popularmente como diurética, hipotensora, antirreumática, antissifilítica, depurativa do sangue e tratamento da dispepsia. Este trabalho teve como objetivos avaliar a toxicidade aguda e a atividade diurética do extrato etanólico bruto (EEBFRV) das folhas da R. viburnoides. Na toxicidade aguda empregou-se o teste de Classe, nas doses de 2000 e 5000 mg/kg, dose única, gavage, em camundongos Swiss e ratos Wistar (ambos os sexos). Na atividade diurética administrou-se em ratas Wistar o extrato bruto (40, 80 e 160 mg/kg, furosemida 20 mg/kg (controle +) e solução salina 0,9% (controle -). Não houve letalidade ou sinais de intoxicação, indicando baixa toxicidade desse extrato. O efeito diurético foi dose-dependente nas 24 h, com aumento dos parâmetros: volume de urina 24 h, excreção dos eletrólitos sódio, potássio e cloreto, uréia e creatinina. Os resultados até o momento, podem justificar a sua utilização popular como diurética.Rudgea viburnoides is popularly used as anti-hypertensive, anti-rheumatic, antissifilitic, blood depurative and for treatment of dyspepsia (leaves, bark, tea). The acute toxicity of ethanolic extract (EEBFRV) in single dose was performed by gavage of doses of 2000 and 5000 mg/kg in Swiss mice and Wistar rats, both sexes, by the class test. To diuretic activity in Wistar rats, it was used the EEBFRV at the doses of 40, 80 and 160 mg/kg, furosemide 20 mg/kg (control +), and saline solution 0.9 % (control -). Regarding acute toxicity, no mortality and no toxicity signs at the dose levels were observed, indicating low toxicity of the extract. The EEBFRV showed statistically significant dose-dependent diuretic effect in 24 h, increasing all parameters evaluated (24h urine volume, excretion of Na+, K+ and Cl- electrolytes, urea (BUN) and creatinine). Thus, the results so far may justify the popular use of Rudgea viburnoides as diuretic.Colegio de Farmacéuticos de la Provincia de Buenos Aire

Multi-centre parallel arm randomised controlled trial to assess the effectiveness and cost-effectiveness of a group-based cognitive behavioural approach to managing fatigue in people with multiple sclerosis

Abstract (provisional) Background Fatigue is one of the most commonly reported and debilitating symptoms of multiple sclerosis (MS); approximately two-thirds of people with MS consider it to be one of their three most troubling symptoms. It may limit or prevent participation in everyday activities, work, leisure, and social pursuits, reduce psychological well-being and is one of the key precipitants of early retirement. Energy effectiveness approaches have been shown to be effective in reducing MS-fatigue, increasing self-efficacy and improving quality of life. Cognitive behavioural approaches have been found to be effective for managing fatigue in other conditions, such as chronic fatigue syndrome, and more recently, in MS. The aim of this pragmatic trial is to evaluate the clinical and cost-effectiveness of a recently developed group-based fatigue management intervention (that blends cognitive behavioural and energy effectiveness approaches) compared with current local practice. Methods This is a multi-centre parallel arm block-randomised controlled trial (RCT) of a six session group-based fatigue management intervention, delivered by health professionals, compared with current local practice. 180 consenting adults with a confirmed diagnosis of MS and significant fatigue levels, recruited via secondary/primary care or newsletters/websites, will be randomised to receive the fatigue management intervention or current local practice. An economic evaluation will be undertaken alongside the trial. Primary outcomes are fatigue severity, self-efficacy and disease-specific quality of life. Secondary outcomes include fatigue impact, general quality of life, mood, activity patterns, and cost-effectiveness. Outcomes in those receiving the fatigue management intervention will be measured 1 week prior to, and 1, 4, and 12 months after the intervention (and at equivalent times in those receiving current local practice). A qualitative component will examine what aspects of the fatigue management intervention participants found helpful/unhelpful and barriers to change. Discussion This trial is the fourth stage of a research programme that has followed the Medical Research Council guidance for developing and evaluating complex interventions. What makes the intervention unique is that it blends cognitive behavioural and energy effectiveness approaches. A potential strength of the intervention is that it could be integrated into existing service delivery models as it has been designed to be delivered by staff already working with people with MS. Service users will be involved throughout this research. Trial registration: Current Controlled Trials ISRCTN7651747

Calidad de vida en pacientes con esclerosis sistémica en confinamiento por pandemia de COVID-19 en Argentina

Introducción: los pacientes con enfermedades reumáticas tienen una calidad de vida significativamente deteriorada. La pandemia por COVID-19 tuvo un notable impacto sobre la población y los sistemas de salud de todo el mundo. Objetivos: en este trabajo nos proponemos conocer el impacto de la pandemia en la calidad de vida de los pacientes con esclerosis sistémica (ES) y cómo fue el acceso a la atención médica. Materiales y métodos: mediante encuestas anónimas y digitales a pacientes durante julio y agosto de 2020 se evaluó la calidad de vida utilizando el cuestionario de calidad de vida de la esclerosis sistémica (SScQoL). Además, se realizaron preguntas para evaluar el acceso al sistema de salud durante ese período. Resultados: se encuestaron 300 pacientes con ES. La mediana de afectación de la calidad de vida según el cuestionario utilizado fue de 17 (9,25-22) y fue el dolor el dominio más afectado. El 29,33% no hizo los controles médicos. El 74,33% refirió haber tenido estudios médicos pendientes al inicio de la cuarentena y solo el 25% pudo realizarlos. Conclusiones: los pacientes con ES presentaron compromiso de la calidad de vida durante la pandemia y mostraron dificultades en el acceso al sistema de salud

Vacunación contra SARS-CoV-2 en pacientes con esclerosis sistémica en Argentina: preferencias, acceso y adherencia al plan de vacunación

Introducción: en pacientes con enfermedades reumatológicas autoinmunes se recomienda la aplicación sistemática y secuencial de una serie de vacunas para la prevención de enfermedades transmisibles. El objetivo de este estudio fue estimar la proporción de pacientes con esclerosis sistémica (ES) que recibieron vacunación contra el coronavirus (SARS-CoV-2). Materiales y métodos: se envió una encuesta anónima por correo electrónico o contacto por WhatsApp desde mayo a septiembre de 2021, con preguntas para evaluar la adherencia al esquema de vacunación recomendado en pacientes con enfermedades reumatológicas, así como temores, preferencias y adherencia al esquema de vacunación contra el SARS-CoV-2

Revista de Ciencias Sociales (Vol. 28 no. 37 jul-dic 2015)

Dossier Procesos de trabajo, organización y gestión de los recursos humanos Presentación Marcos Supervielle y Francisco Pucci La gestión de recursos humanos offshore El caso de las empresas transnacionales y fronterizas Delphine Mercier Configuraciones de la gestión de los recursos humanos El marco del trabajo inmaterial María Julia Acosta Violencia de prestatarios de servicios Un riesgo psicosocial que reclama atención en Argentina Jorge Walter Políticas de seguridad y producción en Uruguay Aceptabilidad del riesgo y gestión Soledad Nión Celio Políticas de seguridad y regulación autónoma El caso de una empresa papelera uruguaya Francisco Pucci Artículos Contrahegemonía y Estado en el agro uruguayo Estrategias de resistencia de organizaciones rurales Paula Florit y Maximiliano Piedracueva Movilidad social intergeneracional en Argentina Oportunidades sin apertura de la estructura de clases Pablo Dall

Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches

Extracellular vesicles (EVs), through their complex cargo, can reflect the state of their cell of origin and change the functions and phenotypes of other cells. These features indicate strong biomarker and therapeutic potential and have generated broad interest, as evidenced by the steady year-on-year increase in the numbers of scientific publications about EVs. Important advances have been made in EV metrology and in understanding and applying EV biology. However, hurdles remain to realising the potential of EVs in domains ranging from basic biology to clinical applications due to challenges in EV nomenclature, separation from non-vesicular extracellular particles, characterisation and functional studies. To address the challenges and opportunities in this rapidly evolving field, the International Society for Extracellular Vesicles (ISEV) updates its 'Minimal Information for Studies of Extracellular Vesicles', which was first published in 2014 and then in 2018 as MISEV2014 and MISEV2018, respectively. The goal of the current document, MISEV2023, is to provide researchers with an updated snapshot of available approaches and their advantages and limitations for production, separation and characterisation of EVs from multiple sources, including cell culture, body fluids and solid tissues. In addition to presenting the latest state of the art in basic principles of EV research, this document also covers advanced techniques and approaches that are currently expanding the boundaries of the field. MISEV2023 also includes new sections on EV release and uptake and a brief discussion of in vivo approaches to study EVs. Compiling feedback from ISEV expert task forces and more than 1000 researchers, this document conveys the current state of EV research to facilitate robust scientific discoveries and move the field forward even more rapidly